| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | — | — | — | — | — | — | — | — | — | — | — | — |
| Sell | — | — | — | — | — | — | — | — | — | — | — | — |
| total | individual payouts | |
|---|---|---|
| 2022 | ‡‡‡‡‡ |
|
| 2021 | ‡‡‡‡‡ |
|
| 2020 | ‡‡‡‡‡ |
|
| 2019 | ‡‡‡ |
|
| 2018 | ‡‡‡ |
|
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Cash | 10.43 | 2.34 | 0.60 | 4.20 |
| Receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Other | — | — | — | — |
| 10.98 | 2.56 | 0.70 | 4.37 |
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Payables | 1.24 | 1.68 | 3.04 | 1.30 |
| ST’ Debt | — | — | — | — |
| Other | — | — | — | — |
| 1.29 | 1.77 | 4.04 | 1.46 |
| 10y | 5y | 3y | |
| Sales | — | — | — |
| Cash Flow | ‡‡‡ | ‡‡‡ | ‡‡‡ |
| Earnings | ‡‡‡ | ‡‡‡ | ‡‡‡ |
| Book Value | ‡‡‡ | ‡‡‡ | ‡‡‡ |
| Year |
|---|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (1.19) | (5.03) | — | — |
—
|
| ’25 | (1.60) | (0.51) | (3.50) | (2.91) |
(8.52)
|
| ’24 | (2.94) | (2.06) | (0.78) | (2.57) |
(8.35)
|
| ’23 | (2.19) | (1.62) | (1.80) | (2.60) |
(8.21)
|
| ’22 | — | — | (1.70) | (2.29) |
(8.01)
|
| ’22 | (2.05) | (1.97) | (0.26) | — |
(7.96)
|
| ’21 | (1.74) | (0.52) | — | — |
(6.14)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (1.19) | (5.03) | — | — |
—
|
| ’25 | (1.60) | (0.51) | (3.75) | (2.72) |
(8.58)
|
| ’24 | (2.94) | (2.06) | (0.78) | (2.57) |
(8.35)
|
| ’23 | (2.19) | (1.62) | (1.80) | (2.60) |
(8.21)
|
| ’22 | — | — | (1.70) | (2.29) |
(8.01)
|
| ’22 | (2.05) | (1.97) | (0.26) | — |
(7.96)
|
| ’21 | (1.74) | (0.52) | — | — |
(6.14)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (36.00) | (8.01) | — | — |
—
|
| ’25 | (116.64) | (151.50) | (107.21) | — |
(338.11)
|
| ’24 | (126.36) | (121.50) | (56.70) | (189.54) |
(494.10)
|
| ’23 | (123.12) | (90.72) | (134.46) | (160.38) |
(508.68)
|
| ’22 | — | — | (132.84) | (191.16) |
(576.72)
|
| ’22 | (121.44) | (145.72) | (170.02) | — |
(3.56)
|
| ’21 | (267.16) | (242.88) | — | — |
(0.40)
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 385.56 | 186.30 | 147.42 | 31.05 | — | — | — |
Low Price
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1,793.34 | 567.00 | 283.50 | 772.20 | — | — | — |
High Price
|
| — | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 7 | 6 | 6 | 7 | — | — | — |
Employees
|
| — | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue/Emp
|
| — | — | — | — | — | — | — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Revenue
|
| — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | — | — | — | — | — | — | — | — |
Gross Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (10.08) | (9.29) | (9.83) | (12.88) | — | — | — |
EBT
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00% | 0.00% | 0.00% | 0.00% | ‡‡‡ | ‡‡‡ | ‡‡‡ |
EBT Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (10.08) | (9.29) | (9.83) | (12.88) | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Net Income
|
| ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | — | — | — | — | 0.21 | — | — | — |
Depreciation
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00 | 0.00 | 0.00 | 0.00 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Revenue/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ | (3.56) | (508.68) | (494.10) | (338.11) | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ |
Earnings/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (2.81) | (448.47) | (419.60) | (223.62) | — | — | — |
Cash Flow/Sh
|
| ‡‡‡ | ‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00 | 0.00 | 0.00 | (1.63) | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Capex/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (2.81) | (448.47) | (419.60) | (225.25) | — | — | — |
Free CF/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 6.85 | 642.19 | 143.57 | (33.39) | — | — | — |
Book Value/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 2.83 | 0.02 | 0.02 | 0.04 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Shares
|
| — | — | — | — | — | — | — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ |
PE Ratio
|
| — | — | — | — | — | — | — | — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PS Ratio
|
| — | — | — | — | — | — | — | — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PB Ratio
|
| — | — | — | — | — | — | — | — | — | — | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ |
EV/Sales
|
| — | — | — | — | — | — | — | — | — | — | — | — | — |
EV/FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (7.96) | (8.21) | (8.35) | (8.52) | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Op' Cash Flow
|
| ‡‡‡ | — | ‡‡‡‡‡ | ‡‡‡‡‡ | — | — | — | — | — | (0.06) | — | — | — |
Capex
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (7.96) | (8.21) | (8.35) | (8.58) | — | — | — |
FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 17.32 | 9.69 | 0.79 | (3.35) | — | — | — |
Working Cap'
|
| — | — | — | — | — | ‡‡‡‡‡ | 0.06 | — | — | — | — | — | — |
Total Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (17.47) | (10.43) | (2.34) | (0.60) | — | — | — |
Net Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 19.40 | 11.75 | 2.86 | (1.27) | — | — | — |
Sh' Equity
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (61.00%) | (55.51%) | (110.77%) | (343.49%) | — | — | — |
ROA
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.00% | (468.04%) | (1,217.24%) | 0.00% | — | — | — |
ROIC
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (64.13%) | (59.63%) | (134.52%) | (1,625.11%) | — | — | — |
ROE
|
Artelo Biosciences (ARTL), a pre-revenue biotech chasing cannabinoid therapies for pain, inflammation, and oncology, embodies the sector’s classic boom-bust volatility—peaking at triple-digit highs in 2019-2020 amid cannabis hype before cratering over 95% to recent $5-11 lows, mirroring historical biotech winters post-Fed hikes and trial setbacks. With zero revenue since 2016, EPS plunging 8,200% to -18.30 in 2024, and operating cash flow deteriorating 3,800% to -$8.35M, the company burns through cash via relentless R&D, fueling 90% share dilution and an 85% equity collapse to $2.86M. Balance sheet red flags abound: working capital at a precarious $785K, emerging net debt, and ROE/ROA in the negative teens signal eroding liquidity without a revenue anchor.
Pipeline milestones like Phase 2 data for ART27.13 and oncology pivots offer speculative upside—analyst targets imply 1,400% potential—but projections forecast deeper losses to -$29M by 2027, “improved” EPS solely from dilution, not profits. Absent insider buys and a tiny team amplify execution risks in a 90%+ failure-rate arena, compounded by cannabis regulatory stalls. For risk-averse investors, ARTL screams caution over lottery allure; historical parallels demand monitoring cash value or catalysts before any nibble, but preservation trumps speculation.
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.